Recalculation of cardiovascular risk score as a surrogate marker of change in clinical care of diabetes patients: the Alphabet POEM project (Practice Of Evidence-based Medicine)

References

• Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997;14\(Suppl 5):S1–85
   Google Scholar
• The Audit Commission. Testing times. In: A review of diabetes services in England and Wales. London: Audit Commission; 2000
   Google Scholar
• British Diabetic Association, King’s Fund, Economists Advisory Group, SmithKline Beecham Pharmaceuticals UK. The T2ARDIS study (type 2 diabetes accounting for a major resource demand in society in the UK): implications for seamless care provision in type 2 diabetes in the UK. 2000
   Google Scholar
• Panzram G. Mortality and survival in type 2 (non insulin-dependent) diabetes mellitus. Diabetologia 1987;30:123–31
   PubMed Web of Science ®Google Scholar
• Kannel WS, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease. Diabetes Care 1979;2:120–6
   PubMedGoogle Scholar
• Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with and without prior myocardial infarction. New Engl J Med 1998;339:229–34
   PubMed Web of Science ®Google Scholar
• Department of Health. National Service Framework for diabetes: delivery strategy. 2002
   Google Scholar
• Department of Health. National Service Framework for coronary artery disease. Modern standards and service models. London: Department of Health; 2000
   Google Scholar
• Patel V, Morrissey J. The Alphabet Strategy: the ABC of reducing diabetes complications. Br J Diabetes Vasc Dis 2002;2:58–9
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837–53
   Google Scholar
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in patients with type 2 diabetes (UKPDS 38). Br Med J 1998;317: 705–13
   Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22
   PubMed Web of Science ®Google Scholar
• The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New Engl J Med 2000;342:145–53
   PubMed Web of Science ®Google Scholar
• Pyorala K, Pedersen TR, Kjekshus J, et al. [The Scandinavian Simvastatin Survival Study (4S) Group]. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian simvastatin survival study (4S). Diabetes Care 1997;20: 614–20
   Google Scholar
• Rubins HB, Robins SJ, Collins D, et al, for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. New Engl J Med 1999;340:410–8
   Google Scholar
• Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Circulation 1998;98:2513–9
   PubMed Web of Science ®Google Scholar
• Athyros VG, Papageorgiou AA, Symeonidis AN, et al. for the GREACE Study Collaborative Group. Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. Angiology 2003;54:679–90
   Google Scholar
• Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Education Program goal versus usual care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 2002;18:220–8
   PubMed Web of Science ®Google Scholar
• Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81–106
   Google Scholar
• American Diabetes Association. Clinical practice recommendations. Diabetes Care 2003;26(Suppl 1):S1–149
   PubMedGoogle Scholar
• Gæde P, Pernille V, Larsen N, et al. Multifactorial intervention with cardiovascular disease in patients with type 2 diabetes. New Engl J Med 2003;348: 383–93
   Google Scholar
• New JP, Roxburgh MA, Vaughan NJ, Wallace C, Elliott P, Young RJ. Measuring differences in the provision of diabetes care. Diabetes Nutr Metab 2001;14:104–7
   PubMedGoogle Scholar
• Graham J, Kerney D, Levine P. Assessment of standard medical care in patients with type 2 diabetes mellitus. Diabetes, 2001 [a journal of the American Diabetes Association]
   Google Scholar
• Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991;121:293–8
   PubMed Web of Science ®Google Scholar
• NHS. Clinical Guideline H. Management of type 2 diabetes – management of blood pressure and blood lipids. National Institute for Clinical Excellence, 2002
   Google Scholar
• The UK HDL-C Consensus Group. Role of fibrates in reducing coronary risk: a UK consensus. Curr Med Res Opin 2004;20:241–7
   PubMed Web of Science ®Google Scholar
• Stevens R, Kothari V, Adler AI, Stratton IM, Holman RR. The UKPDS risk engine: a model for the risk of coronary heart disease in type 2 diabetes (UKPDS 56). Clinical Science 2001;101: 671–9
   Google Scholar
• Kothari V, Stevens RJ, Adler AI, et al. Risk of stroke in type 2 diabetes estimated by the UKPDS risk engine (UKPDS 60). Stroke 2002;33:1776–81
   PubMed Web of Science ®Google Scholar